Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 11/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697316 | 0.82 | ROCK2 (0.51) | HPGDABL1NPC1RAB9A | |
| SCHEMBL30597964 | 0.81 | SMN1; SMN2 (0.49) | HPGDABL1NPC1RAB9AJAK1 | |
| SCHEMBL21874330 | 0.80 | APP (0.41) | HPGDNPC1RAB9A | |
| SCHEMBL30597983 | 0.78 | SLC5A1 (0.39) | HPGDABL1 | |
| SCHEMBL30009349 | 0.77 | ABL1 (0.52) | HPGDABL1ADORA2AADORA1JAK1 | |
| SCHEMBL30597949 | 0.77 | SLC5A1 (0.39) | HPGDABL1NPC1RAB9AJAK1 | |
| SCHEMBL21961535 | 0.77 | CTSC (0.38) | HPGDABL1NPC1RAB9AJAK1 | |
| SCHEMBL4342923 | 0.75 | JAK3 (0.41) | HPGDABL1JAK1 | |
| SCHEMBL25348919 | 0.75 | GSK3A (0.53) | ABL1JAK1 | |
| SCHEMBL29513948 | 0.75 | GSK3A (0.53) | ABL1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | HPGD 2910/4885ABL1 230/4885NPC1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.